'Pharma lyophilisation Market Will Reach $2.48 billion in 2012' Predicts Visiongain Report

Description

'Pharma lyophilisation Market Will Reach $2.48 billion in 2012' Predicts Visiongain Report PR Newswire LONDON, September 6, 2012 LONDON, September 6, 2012 /PRNewswire/ -- A new report by visiongain predicts that the 2012 world market for lyophilisation (freeze drying) products and services for pharma will reach $2.48 billion. That revenue forecast and others appear in Lyophilisation for Pharmaceuticals: Products and Services Market 2012-2022, published in September 2012. Visiongain is a business information provider based in London, UK. Visiongain predicts that pharmaceutical freeze drying revenues will increase strongly from 2012 to 2022, with many commercial opportunities for those products and services. Through emerging technologies and increasing demand for drugs using lyophilisation, the future of that industry and market holds great promise. Dr Syed Ahmed, a senior pharmaceutical industry analyst in visiongain, said: "In recent years the market for lyophilisation technology and services has enjoyed strong growth. Key drivers for the sector have been new products and drug classes, especially in biotechnology. We predict that industry and market will continue to expand through greater demand for lyophilisation technologies and services, particularly demand from the expanding industry for injectable therapeutics. "Our research shows that the world lyophilisation industry and market will benefit from the launch of new biologic drugs and vaccines.

Informations

• Publié par: visiongain
• Nombre de lectures: 192
• Langue: English

Extrait

'Pharma lyophilisation Market Will Reach $2.48
billion in 2012' Predicts Visiongain Report
PLRO NNDeOwNs,w iSreeptember 6, 2012

LONDON
,
September 6, 2012
/PRNewswire/ --
A new report by visiongain predicts that the 2012 world market for
lyophilisation (freeze drying) products and services for pharma will reach
$2.48
billion
. That revenue forecast and others appear in Lyophilisation for
Pharmaceuticals: Products and Services Market 2012-2022, published in
September 2012
. Visiongain is a business information provider based in
London, UK
.
Visiongain predicts that pharmaceutical freeze drying revenues will increase
strongly from 2012 to 2022, with many commercial opportunities for those
products and services. Through emerging technologies and increasing demand
for drugs using lyophilisation, the future of that industry and market holds great
promise.
Dr Syed Ahmed, a senior pharmaceutical industry analyst in visiongain, said: "In
recent years the market for lyophilisation technology and services has enjoyed
strong growth. Key drivers for the sector have been new products and drug
classes, especially in biotechnology. We predict that industry and market will
continue to expand through greater demand for lyophilisation technologies and
services, particularly demand from the expanding industry for injectable
therapeutics.
"Our research shows that the world lyophilisation industry and market will
benefit from the launch of new biologic drugs and vaccines. For biological
drugs, the parenteral route of administration will remain the most important.
Lyophilisation is an established method in the formulation of biological
products. There are under-met needs for improved stability and cost
effectiveness, as well as for more convenience in transport, storage and use of
therapeutic agents. Rapid stabilisation, long-term product stability, ease of
reconstitution and process advantages for heat-sensitive products will stimulate
growth of the lyophilisation technology and services market."
The new report shows revenue forecasts to 2022 at overall world market,
submarket, application and national level. Its research, data and analyses cover
activities of GEA Lyophil, Labconco Corporation, Vetter Pharma-Fertigung,
Piramal Pharma Solutions (PPS), SP Scientific and other providers of
lyophilisation products and services to healthcare.
In addition to forecasting the overall world market for the topic, the analysis
predicts revenue trends for world-level submarkets:
cGMP lyophilisers
Laboratory lyophilisers
Lyophilisation services.

Visiongain's investigation discusses technological and commercial news, shows
research interviews and predicts revenues to 2022 in leading national markets.
The study analyses the US,
Japan
,
Germany
,
France
, the UK,
Spain
,
Italy
(EU5),

India
and
China
.
The report also forecasts sales of drug classes using the drying technologies.
Those applications include therapeutic monoclonal antibodies (MAbs), insulins,
interferons and vaccines.
Lyophilisation for Pharmaceuticals: Products and Services Market 2012-2022
adds to visiongain's range of analytical reports on industries and markets for
pharmaceutical technologies.
For sample pages and further information concerning the Lyophilisation for
Pharmaceuticals: Products and Services Market 2012-2022 please visit:
http://www.visiongain.com/Report/877/Lyophilisation-for-Pharmaceuticals-
Products-and-Services-Market-2012-2022
Companies mentioned in the report include:
Companies Listed
AAIPharma Services
Abbott
ABC Laboratories
ACMAS Technocracy
Affinity Life Sciences
Albany Molecular Research Inc. (AMRI)
ALK-Abelló
camlAAlthea Technologies
negmAAstellas Pharma
Azopharma Product Development Group
B. Braun Melsungen
Baxter BioPharma Solutions
Baxter International
Bayer HealthCare
Bayer HealthCare Pharmaceuticals
Ben Venue Laboratories (a part of Boehringer Ingelheim)
Berna Biotech
Bilcare Global Clinical Supplies
Biogen Idec
BIOLYPH
BioPartners
Biopharma Process Systems
Biopharma Technology
Bio Sidus
Boehringer Ingelheim
Cangene bioPharma
Catalent Pharma Solutions
Centocor Ortho Biotech
Cephalon
Changzhou Yibu Drying Equipment Co.
CIMA Labs
CMC Biologics
Coldstream Laboratories
Cole-Parmer Instrument Company
Corden Pharma
CoreRx Pharmaceuticals

Creapharm
CSL Behring
CSL Biotherapies
CT Arzneimettel
Cuddon Freeze Dry
Dong-A
DSM Pharmaceuticals
EnWave Corporation
E.R. Squibb & Sons
Eli Lilly
European Medicines Agency (EMA)
EMD Serono
Eurogentec
European Freeze Dry
Famar Health Care Services
Food and Drug Administration (US FDA)
Formatech
Freeze Dryer Systems Europe
Freezedry Specialties
Fresenius Kabi Product Partnering
Frozen In Time
Galenix
Gate Pharmaceuticals
GE Healthcare
GEA Group
GEA Lyophil
GEA Niro (a company of the GEA Group)
Genentech (a part of Roche group)
GeneScience
Getz Pharma Research
GIPHARMA
Girindus (a member of the Solvay Group)
Gland Pharma Limited
GlaxoSmithKline
GP Pharm
Grand River Aseptic Manufacturing
Grand River Aseptic Pharmaceutical Packaging
Haemtech Biopharma Services
Haupt Pharma
HollisterStier Contract Manufacturing
HollisterStier Laboratories (a Jubilant Life Sciences company)
Hosokawa Micron Powder Systems
Hospira
Hovione
HTD Biosystems
Huapont Pharm.
Hull (a part of SP industries)
Human Genome Sciences
Hyaluron Contract Manufacturing (HCM)
I.M.A. Industria Macchine Automatiche
IDT Biologika

ilShinBioBase
IMA Edwards Pharmaceutical Systems
Immunex Corporation
Impact Analytical
Intas Biophrmaceuticals
Intelligent Pharma
Irvine Pharmaceutical Services
Janssen Cilag
JHP Pharmaceuticals
JOUAN Nordic A/S
KBI Biopharma
King Pharmaceuticals
KP Pharmaceutical Technology
Lab.
PiSA
Labconco Corporation
Lampire Biological Laboratories
Legacy Pharmaceuticals International
LG Life Sciences
LifeScientz Bio-tech Company
aznoLLyka Labs
Lyofal
Lyophilization Services of New England (LSNE)
Lyophilization Technology
Martin Christ Gefriertrocknungsanlagen
MechaTech Systems
MedPharm
Merck & Co.
Merck Sharp & Dohme
Merk Process
Millrock Technology
Miltenyi Biotec
Ministry of Health, Labour and Welfare (MHLW,
Japan
)
Molecular Profiles
Nextar Chempharma Solutions
NextPharma Technologies
Nicholas Piramal
Niro A/S
Novartis
Novartis Vaccines and Diagnostics
Novo Nordisk
Nycomed
Oakwood Laboratories
OctoPlus N.V.
Om Bhagwati Labelling Technologies
Omnia Biologics
One 2 One
Optima Pharma Group
Optima Machinery Corporation
Oregon Freeze Dry
Organon Teknika Corporation

Osaka
University
Oso BioPharmaceuticals Manufacturing
Overlook Industries
Patheon
Peptisyntha (a part of Solvay Group)
Pfizer
Pfizer CentreSource (PCS)
Pharmatek Laboratories
PharmIdea
Piramal Healthcare
Piramal Pharma Solutions
PolyPeptide Laboratories
ProJect Pharmaceutics
Purdue University
Pyramid Laboratories
Quality Assistance SA
Quorum Technologies
Recipharm Cobra Bio
Regeneron Pharmaceuticals
Reig Jofre Group
LCFRRichman Chemical
RK Medicare Private Limited
ehcoRRoch Mechatronics
CFASSandoz (a Novartis company)
Sanofi
Sanofi Pasteur
Schering Corporation (a subsidiary of Merck & Co.)
Schering-Plough HealthCare Products
Schott
Scripps Laboratories
Serail
Serail Freeze-Drying Systems
SGD Pharma
SL Pharma Labs
Solvay
SP Formulations
SP Industries
SP Scientific
SPI Pharmaceuticals
SRI International
Stason Pharmaceuticals
Talecris Biotherapeutics
Telstar
Teva Pharmaceutical Industries
Therapure Biopharma
Thermo Fisher Scientific
BCUUniversity of Connecticut

University of Iowa Pharmaceuticals (UIP)
USIFROID (a Telstar company)
Valeant Pharmaceuticals International
Vectech
Vetter Pharma-Fertigung
Vetter Pharma International
Walter Reed Pilot Bioproduction Facility
West Pharmaceutical Services
Wheaton Science Products
Wockhardt
Wyeth Pharmaceuticals (a subsidiary of Pfizer)
Xellia Pharmaceuticals
Zirbus Technology
Notes for Editors
If you are interested in a more detailed overview of this report, please send an
e-mail to [e-mail] or call her on [phone]
About visiongain
Visiongain is one of the fastest growing and most innovative independent media
companies in
Europe
. Based in
London, UK
, visiongain produces a host of
business-2-business conferences, newsletters, management reports and e-
zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials
sectors.
Visiongain publishes reports produced by its in-house analysts, who are
qualified experts in their field. Visiongain has firmly established itself as the first
port-of-call for the business pr